Doug Ingram

Pharma

Sarepta, despite key trial flop, will seek full nod for DMD meds

Sarepta’s Vyondys 53 and Amondys 45 failed to show a statistically significant difference versus placebo on a key measurement of DMD patient mobility.

Angus Liu Nov 4, 2025 7:56am

Sarepta sees delays in treatment after Elevidys death report

May 7, 2025 8:03am

Sarepta's Elevidys blows sales expectations out of the water

Nov 7, 2024 3:43pm

Sarepta CEO Ingram nabs $57M in 2017 pay

May 7, 2018 12:36pm

The companys newest additions include a global director of revenue management global director of sales and a food beverag

Sarepta’s CEO pick draws praise, takeover talk from analysts

Jun 29, 2017 5:58am